Ultragenyx Pharmaceutical (RARE) Change in Acquisitions & Divestments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Acquisitions & Divestments data on file, last reported at $88.0 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 35.77% year-over-year to $88.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.0 million (down 537.27% YoY) and the FY2024 annual result came in at $3.0 million, down 99.57% from the prior year.
• Change in Acquisitions & Divestments grew to $88.0 million in Q1 2026 per RARE's latest filing, from -$143000.0 in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $567.6 million in Q3 2023 and bottomed at -$323.7 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $98.2 million (2022), against an average of $54.5 million.
• The widest annual swing landed in 2022, when Change in Acquisitions & Divestments slumped 3479.11%; it then surged 413.1% in 2023.
• Tracing RARE's Change in Acquisitions & Divestments over 5 years: stood at -$323.7 million in 2022, then jumped by 135.15% to $113.8 million in 2023, then tumbled by 100.13% to -$148000.0 in 2024, then gained by 3.38% to -$143000.0 in 2025, then jumped by 61638.46% to $88.0 million in 2026.
• Per Business Quant, the three latest RARE Change in Acquisitions & Divestments figures stand at $88.0 million (Q1 2026), -$143000.0 (Q4 2025), and -$136.9 million (Q2 2025).

Peer Comparison